PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
May 4, 2026Frontiers in OncologyOpen Access

Distinct protein and metabolic profiles in patients with advanced clear-cell renal cell carcinoma treated with sunitinib: a study of the Spanish oncology genitourinary group

View Full Paper
Ask AI
Bookmark
Share

Authors

GQGuillermo QuintásESElena SanmartínAGAlícia Giménez

Discussion

Loading...

Member takes

Overview

Prospective multicenter trial identifies biomarkers predicting survival in patients with metastatic CCRCC on sunitinib, suggesting improved treatment selection.

Key Points

  • This study aims to discover predictive biomarkers in metastatic clear cell renal cell carcinoma (CCRCC) for improved treatment selection.
  • Conducted a prospective, multicenter study in patients with locally advanced or metastatic CCRCC receiving first-line sunitinib.
  • Measured serum protein levels related to angiogenesis and immune escape, alongside metabolic pattern analyses focused on tryptophan metabolism.
  • Recorded routine blood test results and analyzed correlations among all parameters.
  • Median progression-free survival (PFS) was 9.87 months and median overall survival (OS) was 21.10 months.
  • Higher interleukin-6 (IL-6), arginase-1, and S100A9 concentrations were significant predictors of shorter OS.
  • Metabolomic analysis showed elevated tryptophan metabolites associated with poorer PFS, with distinct risk groups identified based on protein levels.

Cite This Study

Quintás et al. (2026) studied this question.

synapsesocial.com/papers/69f836aa3ed186a739980df7https://doi.org/10.3389/fonc.2026.1639330
View Full Paper
Ask AI
Bookmark
Share